Introduction: Patients of chronic myeloid leukemia (CML) eventually transform to blast crisis (BC) after a variable length of chronic phase (CP). With improvement in management protocols, many patients of CML-BC are expected to show remission after initial chemotherapy and a better survival. Hence, it becomes imperative to correctly classify the nature of BC for further course of management.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that results from the clonal expansion of a pluripotent stem cell. It is characterized by the presence of balanced translocation, i.e., t(9;22), leading to formation of a fusion transcript -"BCR-ABL". The identification of this transcript and providing a correct diagnosis becomes extremely important due to the efficacy of "signal transduction inhibitors," like Imatinib, to target the fusion protein and produce remarkable improvement in the course of the disease. The natural clinical course of CML is generally triphasic; initial chronic phase (CP), followed by accelerated phase and subsequent blast crisis (BC), which is an inevitably terminal event. The BC of CML is reported to have cell line heterogeneity, since the blasts can express myeloid, lymphoid, monocytic, megakaryocytic, and rarely erythroid phenotype. Immunophenotyping per se has a limited role in diagnosis of CML but is being used frequently in CML-BC cases. The diverse lineages seen in the BC have only been noted with the advent and routine use of multicolor flow cytometry. A comprehensive panel of antibodies used in the primary screening makes the lineage determination easy and allows assessment of aberrant expression of antigens. 1, 2 This study was planned to evaluate immunophenotyping results of flow cytometry done for cases of CML-BC at a single tertiary care institute of North India. The immunophenotyping performed by flow cytometry in all 15 cases was also reviewed. The EDTAanticoagulated bone marrow aspirate sample was used in 13 cases and peripheral venous blood sample was used in two cases for immunophenotyping. The samples for flow cytometry were processed as per standardized "lyse-stain-wash" technique routinely used for all acute leukemia cases. Briefly, 100 µL of peripheral blood/bone marrow aspirate sample was mixed with 2 mL RBC lysing solution and then centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and the cell button was further washed in phosphate buffer saline (PBS) solution and subsequently suspended in 500 µL of PBS. In 100 µL of cell suspension, standardized pre-titrated volumes of monoclonal antibody-cocktails (Becton Dickinson, USA) were added and incubated in dark. The antibody panel comprised of CD19, CD10, CD20, cytoplasmic-CD79a, CD3, CD4, CD7, CD8, cytoplasmic-CD3, CD13, CD33, CD117, antiMPO, CD14, CD64, CD11c, CD41a, CD61, CD235a, CD34, HLADR, and terminal deoxynucleotidyl transferase (TdT). These monoclonal antibodies were used in conjugation with four fluorochromes, i.e., FITC, PE, APC, and PerCP in each tube. CD45PerCP was used as an anchor marker to assist gating of blasts in all the tubes. The samples were acquired on dual laser BD FACS -Canto II and the analysis was done by FACS Diva software. The flow cytometry data was analyzed, and the lineage of the blasts was determined in each case depending upon the expression of lineage specific markers.
MATERIALS AND METHODS

RESULTS
Fifteen cases of CML-BC were comprehensively immunophenotyped by flow cytometry in 5 years and these were selected for the present study. Thirteen were diagnosed as CML-BC at the time of presentation and two were on treatment with Imatinib. The mean age of the patients included was 40.2 ± 17 (16-74) years. There were 11 males and 3 females (M:F: 3:1) ( Table 1) . Blast percentage in bone marrow aspirate smears ranged from 27 to 60%, with mean of 42.6 ± 13.4%. Cytochemical staining revealed positivity of MPO in three cases indicating myeloid lineage. Lineage assignment was not possible for the rest of the 12 cases on the basis of morphology and the cytochemistry performed. Fourteen cases were diagnosed as myeloid blast crises, with twelve of these cases expressing markers of granulocytic differentiation, one each with myelomonocytic and megakaryocytic differentiation. Only one case was diagnosed as B-lineage BC. CD33 was the commonest myeloid marker noted in cases diagnosed as myeloid blast crises. This was followed by CD13 expression. None of the cases showed presence of more than one lineage (according to WHO 2008 criteria of lineage assignment) although aberrant antigen expression was commonly noted. Most common aberrancy was expression of CD7 in five cases of myeloid blast crises. Minor population of blasts expressed monocytic and megakaryocytic markers in two separate cases, besides one case each diagnosed as myelomonocytic leukemia and megakaryoblastic leukemia. In addition, two cases of myeloid blast crises expressed a minor population of blasts with erythroid lineage marker (CD235a) (Graph 1). The present study revealed surface expression of CD34 in all our cases of myeloid BC (n = 14) and CD7 expression was noted in five cases. CD34 expressing myeloid precursors normally express CD7 transiently and CD34+CD7+ myeloid precursors have been noted at higher frequency in CP of CML as compared to normal donors. 9 Co-expression of CD34 and CD7 suggests that the blasts in cases of CML-BC are arrested at early stage of immature myeloid progenitors. 10 Paietta and Schwarzmeier 11 had demonstrated immunophenotypic shifts during the course of therapy in their cohort of CML-BC patients. The phenomenon of alterations in the expression profile of surface markers on blasts after chemotherapy is not uncommon even in acute leukemia cases. However, such immunophenotypic shifts might occur in CML-BC patients on chemotherapy due to the emergence of new clone or previously minor clone, resistant to the therapy. The clonal evolution cannot be picked up by morphology alone and emphasizes the role of immunophenotyping in CML-BC. Kantarjian et al 12 had analyzed a large cohort of 242 patients of CML-BC in the late 1980s. Out of 195 patients who were treated for BC, remission was achieved only in 45 (23%) patients. The overall survival of patients of CML-BC still remains poor. The present study is limited by the unavailability of follow-up of the patients. Overall, immunophenotyping remains necessary for assigning specific lineage to blasts in patients of CML-BC and thus providing clinically useful information regarding the treatment protocols and prognosis of the patient. Its use is more pertinent since occurrence of mixed lineage blasts in CML-BC is not very rare. from the same institute had carried out a similar study on 25 cases of CML-BC. Their patient cohort had a similar mean age as compared to the present study; however, the male-to-female ratio was 1:1.7. They reported low sensitivity of cytochemical stains including MPO, chloroacetate esterase (CAE), Sudan Black B (SBB), and PAS in cases of CML-BC. The authors had done immunophenotyping using indirect immunofluorescence technique on bone marrow aspirate smears and could demonstrate its importance in categorizing the nature of BC. The present study noted 14 cases of myeloid lineage, and only one case of B-lineage BC. Evolution of CML into BC is commonly of myeloid type and less frequently of lymphoid type. 5 We had only one case of lymphoid-BC, and the marked preponderance of myeloid BC in our series might just represent a bias due to small sample size. There was no case of mixed-lineage BC, defined according to WHO 2008 criteria of lineage assignment;
